Literature DB >> 17055622

Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.

Dang Duc Anh1, Do Gia Canh, Anna Lena Lopez, Vu Dinh Thiem, Phan Thi Long, Nguyen Hong Son, Jacqueline Deen, Lorenz von Seidlein, Rodney Carbis, Seung Hyun Han, Seong Hye Shin, Stephen Attridge, Jan Holmgren, John Clemens.   

Abstract

Vietnam currently produces an orally administered, bivalent (O1 and O139) killed whole-cell vaccine and is the only country in the world with endemic cholera to use an oral cholera vaccine in public health practice. In order to allow international use, the vaccine had to be reformulated to meet World Health Organization (WHO) requirements. We performed a randomized, placebo controlled, safety and immunogenicity studies of this reformulated vaccine among Vietnamese adults. One hundred and forty-four subjects received the two-dose regimen and 143 had two blood samples obtained for analysis. We found that this reformulated oral killed whole-cell cholera vaccine was safe, well tolerated and highly immunogenic.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17055622     DOI: 10.1016/j.vaccine.2006.09.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  36 in total

Review 1.  New-generation vaccines against cholera.

Authors:  John Clemens; Sunheang Shin; Dipika Sur; G Balakrish Nair; Jan Holmgren
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-08       Impact factor: 46.802

2.  Cholera in India: an analysis of reports, 1997-2006.

Authors:  S Kanungo; B K Sah; A L Lopez; J S Sung; A M Paisley; D Sur; J D Clemens; G Balakrish Nair
Journal:  Bull World Health Organ       Date:  2010-03       Impact factor: 9.408

3.  A large study on immunological response to a whole-cell killed oral cholera vaccine reveals that there are significant geographical differences in response and that O blood group individuals do not elicit a higher response.

Authors:  T Ramamurthy; Diane Wagener; Goutam Chowdhury; Partha P Majumder
Journal:  Clin Vaccine Immunol       Date:  2010-06-16

Review 4.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

5.  Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.

Authors:  F O Eko; D N Okenu; U P Singh; Q He; C Black; J U Igietseme
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

Review 6.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

7.  Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility.

Authors:  Anne L Bishop; Stefan Schild; Bharathi Patimalla; Brian Klein; Andrew Camilli
Journal:  Infect Immun       Date:  2010-08-02       Impact factor: 3.441

8.  Guinea pig complement potently measures vibriocidal activity of human antibodies in response to cholera vaccines.

Authors:  Kyoung Whun Kim; Soyoung Jeong; Ki Bum Ahn; Jae Seung Yang; Cheol-Heui Yun; Seung Hyun Han
Journal:  J Microbiol       Date:  2017-12-07       Impact factor: 3.422

9.  Genomic correlates of variability in immune response to an oral cholera vaccine.

Authors:  Partha P Majumder; Neeta Sarkar-Roy; Herman Staats; T Ramamurthy; Sujit Maiti; Goutam Chowdhury; Carol C Whisnant; K Narayanasamy; Diane K Wagener
Journal:  Eur J Hum Genet       Date:  2012-12-19       Impact factor: 4.246

10.  Construction of a Vibrio cholerae prototype vaccine strain O395-N1-E1 which accumulates cell-associated cholera toxin B subunit.

Authors:  Gi-eun Rhie; Hae-Mi Jung; Bong Su Kim; John J Mekalanos
Journal:  Vaccine       Date:  2008-06-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.